Skip to content Skip to footer
Subscribe Now

INSIGHTS+

Insights+ Key Biosimilars Events of January 2023
Insights+ Key Biosimilars Events of January 2023
Shots: Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of January, Celltrion reported P-III trial results of…
February 1, 2023
Top Performing Drug of 2021 – Imbruvica (January Edition)
Top Performing Drug of 2021 – Imbruvica (January Edition)
Active Ingredient: Ibrutinib   Dosage Forms & Strengths:   Capsules: 70 mg and 140 mg   Tablets: 140 mg, 280 mg, 420 mg, and 560 mg   Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi)  First Approval: US (13 Nov 2013), EU (Oct 2014)   Revenue Analysis Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…
January 25, 2023
Insights+: EMA Marketing Authorization of New Drugs in December 2022
Insights+: EMA Marketing Authorization of New Drugs in December 2022
Shots: The EMA approved 6 New Chemical Entity (NCE) and 6 Biologic Drugs in December 2022, leading to treatments for patients and advances in the healthcare industry In December 2022, the major highlights drugs were Pluvicto’s approval for progressive PSMA+ metastatic castration resistant prostate cancer, Dupixent for Prurigo Nodularis PharmaShots has compiled a list of…
January 24, 2023
Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas
Insights+: Key Takeaways of J.P. Morgan Healthcare Conference 2023 Based on Therapeutic Areas
Shots: The 41st Annual J.P. Morgan Healthcare Conference took place on 09 – 12 January 2023 in San Francisco, CA, USA. It is the largest and most informative healthcare investment symposium in the industry, bringing together a cohort of industry leaders, emerging fast-growing companies, innovative technology creators, and members of the investment community  The major announcement…
January 19, 2023
Insights+: The US FDA New Drug Approvals in December 2022
Insights+: The US FDA New Drug Approvals in December 2022
Shots: The US FDA approved 8 NDAs and 5 BLA in December 2022, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 86 novel products in 2022 In December 2022, the major highlights drugs were Krazati (adagrasib) approval for non-small cell lung cancer with a KRASG12C mutation, Sunlenca…
January 18, 2023
Disease of the Month: Cervical Cancer
Disease of the Month: Cervical Cancer
“Get Informed, Get Screened, Get Vaccinated” – WHO Introduction: Cervical cancer is the 4th most common cancer among women and 7th most commonly occurring cancer overall. When a malignant growth or tumor occurs in the cells lining the walls of the cervix, it is called cervical cancer. The cervix is the narrow, lower part of the uterus…
January 12, 2023
J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)
J.P. Morgan Special: Dealmaker 2022 – Top M&A Deal of Roche (Part 01)
Shots:  Roche was the top dealmaker in 2022 with a completion of 31 deals with multiple pharma, biotech companies, and universities for a total deal value of $13.55B  The highest deal was secured by Roche under its development and commercialization collaboration with Poseida for the R&D of multiple existing and novel cell therapies for the…
January 5, 2023
Insights+ Key Biosimilars Events of December 2022
Insights+ Key Biosimilars Events of December 2022
Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of December, Alvotech and STADA launched Hukyndra (biosimilar, adalimumab)…
January 4, 2023
PharmaShots' Most Read News of 2022
PharmaShots’ Most Read News of 2022
The year 2022 has been a busy year for global pharma and biotech companies involved in M&A, option & licensing agreements, clinical trial results and gaining approvals. Our team has compiled a list of 30 most read life sciences news on PharmaShots in 2022 1. AVEO Entered into a Clinical Trial Collaboration with Merck KGaA to…
January 2, 2023
Load more